The Hospital for Sick Children-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014354)
◆英語タイトル:The Hospital for Sick Children - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014354
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:31
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
The Hospital for Sick Children (SickKids) is a healthcare service provider that offers children care services. The hospital offers programs and services including resources, tele-medicine, accommodations, child life, creative arts therapy, child and family-centered care; health records inquiries, and others. It provides epilepsy classroom, paediatric advanced care team, the play park, paediatric laboratory medicine, tele-link mental health program and resource navigation programs. SickKids offers services across wide range of clinical specialties including cardiology, clinical pharmacology and toxicology, endocrinology, infectious diseases and neurology among others. It also provides development of accessible, comprehensive and sustainable child health systems. The hospital operates through its integrating care, research and teaching centers in Toronto. SickKids is headquartered in Toronto, Ontario, Canada.

The Hospital for Sick Children – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
The Hospital for Sick Children, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Hospital for Sick Children, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Hospital for Sick Children, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Hospital for Sick Children, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
The Hospital for Sick Children, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
The Hospital for Sick Children, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Cyclenium Pharma Enters into Research Agreement with The Hospital for Sick Children 10
Turing Pharma Enters into Research Agreement with Hospital for Sick Children 11
Hospital for Sick Children Enters Into Research Agreement With GlaxoSmithKline To Discover Treatment For Cystic Fibrosis 12
Hospital for Sick Children Enters Into Co-Development Agreement With Life Technologies 13
MaRS Innovation and Hospital for Sick Children Enter into Co-Development Agreement with NovoTek Therapeutics 14
Licensing Agreements 15
ERAD Therapeutics Enters into Licensing Agreement with Hospital for Sick Children 15
Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University Of Toronto 16
The Hospital for Sick Children – Key Competitors 17
The Hospital for Sick Children – Key Employees 18
The Hospital for Sick Children – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Government and Public Interest 20
Oct 12, 2017: SickKids team receives $2.99 million from SU2C Catalyst program to develop combination therapy for most aggressive cancer predisposition syndrome 20
Jul 13, 2016: First drug target identified for children with rare type of brain tumor 21
Jun 07, 2016: Six new drug discovery acceleration projects supported by CQDM and Ontario Centres of Excellence 22
May 02, 2016: Understanding lung damage due to childhood asthma could hold the clues to preventing respiratory disease later in life 24
Apr 30, 2016: Back to the basics – study suggests a simplified approach to treating vomiting and diarrhea 25
Mar 31, 2016: TrialNet identifies three progressive stages of Type 1 diabetes 26
Mar 29, 2016: New Toronto Paediatric Cancer Stage principles provide expert consensus on the collection of paediatric cancer stages in population-based cancer registries 27
Jan 28, 2016: Pain management in premature infants linked to impaired brain development 28
Jan 26, 2016: Heightened perception of anger driven by over-connected brain circuits in soldiers with PTSD, new study finds 29
Jan 13, 2016: Biology of tumour changes when childhood brain cancer recurs, Canadian study finds 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
The Hospital for Sick Children, Pharmaceuticals & Healthcare, Key Facts 2
The Hospital for Sick Children, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Hospital for Sick Children, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Hospital for Sick Children, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Hospital for Sick Children, Deals By Therapy Area, 2011 to YTD 2017 8
The Hospital for Sick Children, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cyclenium Pharma Enters into Research Agreement with The Hospital for Sick Children 10
Turing Pharma Enters into Research Agreement with Hospital for Sick Children 11
Hospital for Sick Children Enters Into Research Agreement With GlaxoSmithKline To Discover Treatment For Cystic Fibrosis 12
Hospital for Sick Children Enters Into Co-Development Agreement With Life Technologies 13
MaRS Innovation and Hospital for Sick Children Enter into Co-Development Agreement with NovoTek Therapeutics 14
ERAD Therapeutics Enters into Licensing Agreement with Hospital for Sick Children 15
Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University Of Toronto 16
The Hospital for Sick Children, Key Competitors 17
The Hospital for Sick Children, Key Employees 18
The Hospital for Sick Children, Subsidiaries 19

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ The Hospital for Sick Children-製薬・医療分野:企業M&A・提携分析(The Hospital for Sick Children - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆